BAK linked to ocular surlace damage in animal studies.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Subject Terms:
    • Abstract:
      The article reports on the study conducted in an animal model with medication preserved with benzalkonium chloride (BAK) in Taormina, Italy. Researchers found that latanoprost with BAK caused a significant loss of cell-cell adhesion that can predispose patients to have ocular surface damage. It revealed that once-daily dosing of latanoprost with 0.02% BAK produced more goblet cell loss compared with either preservative-free-artificial tear or travoprost ophthalmic solution.